The updated American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines classify tumors with ER expression 1–10%, >10%, and <1% as ER-low+, ER+, and ER− breast tumors, respectively. This evidence concerns the gene ESR1 and breast neoplasm.